SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (13316)1/14/1998 7:16:00 PM
From: Andrew H  Respond to of 32384
 
>>Targretin has already completed Phase I/IIa trials for cancer, so I would expect a Breast Cancer treatment trial to begin at the II/III Phase.<<

Good point, Henry. At least a P2.

I am wondering how you would respond to my question to V1 below, regarding his statement. Both Stan and I are concerned about this, since the revenue implications are HUGE.Probably we just need some more information.

>>On the negative side it is becomming clear that Neither Targretin nor panretin will be a major player in solid tumors. <<

How does this square with the information that Targretin is showing activity in lung, breast and prostate cancer?



To: Henry Niman who wrote (13316)1/14/1998 11:56:00 PM
From: Paul Moerman  Read Replies (2) | Respond to of 32384
 
Henry, I'm still here (just in lurking mode). Even bought some more LGND yesterday, after having been forced to sell some last month because of the dreaded margin calls! :-(

Thanks for remembering me. I bookmarked your website last week and have only scratched the surface, but it looks terrific! Best,

Paul


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News